| Title: |
Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France |
| Authors: |
Deslee, Gaëtan; Russo, Héloïse; Fabry-Vendrand, Caroline; Koskas, David; Thabut, Gabriel; Bell, John; Caplen, Melissa; Bhatt, Prachi; Carioto, Jennifer; Pyenson, Bruce; Burgel, Pierre-Régis |
| Contributors: |
Service des maladies respiratoires et allergiques CHU Reims; Hôpital universitaire Robert Debré Reims (CHU Reims); Pathologies Pulmonaires et Plasticité Cellulaire - UMR-S 1250 (P3CELL); Université de Reims Champagne-Ardenne (URCA)-Institut National de la Santé et de la Recherche Médicale (INSERM); AstraZeneca Courbevoie; AstraZeneca Cambridge, UK; Milliman France; Hôpital Cochin AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Institut Cochin (IC UM3 (UMR 8104 / U1016)); Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité) |
| Source: |
ISSN: 1176-9106. |
| Publisher Information: |
CCSD; Dove Medical Press |
| Publication Year: |
2025 |
| Collection: |
Université de Reims Champagne-Ardenne: Archives Ouvertes (HAL) |
| Subject Terms: |
COPD; Single-inhaler triple therapy; Population model; [SDV]Life Sciences [q-bio] |
| Description: |
International audience ; Background: COPD is the seventh-leading cause of death in France. The randomized controlled trials ETHOS (NCT02465567) and IMPACT (NCT02164513) have demonstrated a reduction in exacerbations (primary endpoint) and suggest a decrease in mortality (secondary endpoint) with single-inhaler triple therapy (SITT)—containing a long-acting beta-2 agonist, long-acting anticholinergics, and an inhaled corticosteroid—in patients with COPD. No study has evaluated the potential impact of increased SITT use in France. Objective: To evaluate the impact of increased SITT use in COPD on exacerbations, mortality, and medical costs in France. Methods: A stochastic model was constructed using GOLD therapeutic recommendations and literature data on patient characteristics, prevalence, incidence, treatment distribution, COPD severity and treatment changes, mortality, and exacerbations to model the French COPD population. Two scenarios were studied: Status Quo (no increase in SITT use) and Increased SITT, using the GOLD stage and exacerbation history to initiate SITT treatment in modeled patients, considering the annual probabilities of transitioning from one GOLD stage to another over a 10-year period. Results: Increased SITT use compared to the Status Quo over a 10-year period could reduce severe and moderate exacerbations by 8.0% and 9.2%, respectively, all-cause mortality by 8.5%, and medical costs by 875 million euros (excluding additional SITT costs), and extend the life of patients by 0.6 years per patient with COPD. Conclusion: The model shows that increased SITT use in France, in line with recent recommendations, could be associated with a reduction in exacerbation rates, mortality, and costs in patients with COPD. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41281771; PUBMED: 41281771; PUBMEDCENTRAL: PMC12638261 |
| DOI: |
10.2147/COPD.S539055 |
| Availability: |
https://univ-reims.hal.science/hal-05383261; https://univ-reims.hal.science/hal-05383261v1/document; https://univ-reims.hal.science/hal-05383261v1/file/GaetanDeslee_IntJCOPD_2025.pdf; https://doi.org/10.2147/COPD.S539055 |
| Rights: |
https://creativecommons.org/licenses/by-nc/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.476BA0CB |
| Database: |
BASE |